Emerging Company Profile
Stablix takes targeted protein degradation’s tactics in reverse
Emerging Company Profile: Versant’s protein stabilization play has $63M to develop ‘RESTORACS’ for rare diseases, cancer and autoimmunity
Versant-founded targeted protein stabilization company Stablix is using its $63 million series A round to develop ‘RESTORACS’ for rare diseases, cancer and autoimmunity.
Stablix is the among the first companies founded to extend the logic of protein degradation to a different enzymatic process — in this case, stabilizing proteins via deubiquitination.
The company emerged from stealth Thursday with a $63 million